A grant from the Parkinson Voice Project will be used to enhance the training and resources available to speech language pathologists and graduate students with the RiteCare Center for Communication Disorders at Georgia Southern University. Such awards, whose sum was not disclosed, are given annually by Parkinson Voice Project (PVP) through…
Mapping of a brain circuit that is of particular relevance to neurological diseases such as Parkinson’s and Huntington’s revealed key features about its architecture and information flow, a study in mice reported. This brain circuit involves a looping connection between the cortex, the basal ganglia, and the thalamus…
People with Parkinson’s disease are significantly less likely than those without the neurodegenerative disorder to develop colorectal cancer, a type of cancer that begins in the final part of the digestive tract, a new meta-analysis suggests. In fact, the analysis showed that the risk of developing such cancer…
Nearly four of every 10 patients with Parkinson’s disease experience minor hallucinations, a new study from China estimates. Results suggest a link between minor hallucinations and Parkinson’s-related sleep problems. The study, “Prevalence and Risk Factors for Minor Hallucinations in Patients with Parkinson’s Disease,” was published in …
No differences in cognitive abilities were identified between men and women with Parkinson’s disease, according to a recent study. Although no tests were conducted, the researchers suggested the lack of cognitive differences between male and female patients, which is found in aging healthy individuals, may be due to the…
Mission Therapeutics has been awarded a Therapeutic Pipeline Program grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance development of its USP30 deubiquitylating enzyme (DUB) inhibitors for the treatment of familial Parkinson’s disease. The grant, worth about $500,000, will be used to test these inhibitors in animals that model…
A deep brain stimulation (DBS) protocol that targets specific sets of nerve cells, or neurons, in the brain produced long-lasting effects in a mouse model of Parkinson’s disease. The new protocol, which uses brief bursts of electrical stimulation, offered effects that lasted hours longer than those of conventional DBS. The study,…
The University of Michigan (U-M) will use a five-year, $11.7 million grant to reopen its Morris K. Udall Center of Excellence in Parkinson’s Disease Research, according to a university press release. The grant, from the National Institute of Neurological Diseases and Stroke (NINDS), will fund research on falls and…
A new research project seeks to better characterize the structural properties of alpha-synuclein, which researchers hope will lead to a better understanding of this protein’s toxic effects in Parkinson’s disease. One of the hallmark features of Parkinson’s is the formation of aggregates — “clumps” or “tangles” — of alpha-synuclein…
Treatment with zonisamide — an approved epilepsy medication — can reduce “off” time without worsening treatment side effects in people with Parkinson’s disease, a new analysis of Japanese clinical trial data shows. Notably, the use of zonisamide did not increase dyskinesia, the uncontrolled, involuntary movements common among…
Get regular updates to your inbox.
